Trastuzumab-Induced Tumor Microenvironment Changes in Early HER2+Breast Cancer

被引：0
|
作者：
Kennedy, Laura C.
Alvarez, Rebeca
Dintzis, Suzanne
Gadi, Vijayakrishna K.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P2-23-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-23-05
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Physician perceptions to use of trastuzumab in HER2+breast cancer in India
    Ramanjinappa, N.
    Agarwal, J.
    Upveja, K. H.
    ANNALS OF ONCOLOGY, 2022, 33 : S1437 - S1437
  • [22] Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer
    Nicolazzi, M. A.
    Carnicelli, A.
    Fuorlo, M.
    Scaldaferri, A.
    Masetti, R.
    Landolfi, R.
    Favuzzi, A. M. R.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2018, 22 (07) : 2175 - 2185
  • [23] Trastuzumab-induced HER Reprogramming in "Resistant" Breast Carcinoma Cells
    Narayan, Murli
    Wilken, Jason A.
    Harris, Lyndsay N.
    Baron, Andre T.
    Kimbler, Kimberly D.
    Maihle, Nita J.
    CANCER RESEARCH, 2009, 69 (06) : 2191 - 2194
  • [24] Biomarkers of Trastuzumab-Induced Cardiac Toxicity in HER2-Positive Breast Cancer Patient Population
    Grela-Wojewoda, Aleksandra
    Puskulluoglu, Miroslawa
    Sas-Korczynska, Beata
    Zemelka, Tomasz
    Pacholczak-Madej, Renata
    Wysocki, Wojciech M.
    Wojewoda, Tomasz
    Adamczyk, Agnieszka
    Lompart, Joanna
    Korman, Michal
    Mucha-Malecka, Anna
    Ziobro, Marek
    Konduracka, Ewa
    CANCERS, 2022, 14 (14)
  • [25] HER2+breast cancer
    Hicks, David G.
    Kulkarni, Swati
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 129 (02) : 263 - 273
  • [26] HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
    Blancas, Isabel
    Linares-Rodriguez, Marina
    Martin-Bravo, Celia
    Gomez-Pena, Celia
    Rodriguez-Serrano, Fernando
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (10): : 2531 - 2540
  • [27] Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+breast cancer patients: an institutional retrospective study
    Moey, Melissa Y. Y.
    Liles, Darla K.
    Carabello, Blase A.
    CARDIO-ONCOLOGY, 2019, 5 (01)
  • [28] Adjuvant and neoadjuvant trastuzumab in combination with vinorelbine for HER2+breast cancer.
    Esfahani, Khashayar
    Ferrario, Cristiano
    Le, Philippe
    Panasci, Lawrence C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Inhibiting telomerase to reverse trastuzumab (T) resistance in HER2+breast cancer
    Miller, K. D.
    Steding, C. E.
    Prasad, N.
    Rojas, L. A.
    Herbert, B-S
    CANCER RESEARCH, 2012, 72
  • [30] Potential Biomarkers Associated with Prognosis and Trastuzumab Response in HER2+Breast Cancer
    Castro-Guijarro, Ana Carla
    Sanchez, Angel Matias
    Flamini, Marina Ines
    Vogel, Christoph F. A.
    CANCERS, 2023, 15 (17)
12345